Northwire Canada EditionMonday, July 13, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings

Telo Genomics increases private placement to $1.6M

TELO · Price

Executive Summary

  • Telo Genomics Corp. has upsized its previously announced non-brokered private placement of non-transferable secured convertible debentures from a maximum of $1.2 million to $1.6 million.
  • The company has already closed an initial tranche raising $840,000 and intends to close one or two additional tranches for up to $760,000, with the final tranche expected to close by March 6, 2026.
  • The offering consists of debentures bearing 15% annual interest, convertible into common shares at $0.05 per share, accompanied by detachable warrants exercisable at $0.08 per share.

Key Details

  • Offering Structure: Non-brokered private placement of non-transferable secured convertible debentures.
  • Upsized Amount: Increased from up to $1.2 million to up to $1.6 million.
  • Interest Rate: 15% per annum, compounded quarterly.
  • Maturity Date: December 15, 2026.
  • Conversion Terms: Holders may elect to convert principal into common shares at a conversion price of $0.05 per share at any time before maturity. The company has no right to prepay prior to maturity.
  • Warrant Terms: For every $100,000 of debentures issued, the company issues 2,000,000 detachable warrants. Each warrant is exercisable for one common share at an exercise price of $0.08 per share for a period of 12 months from the closing date.
  • Initial Tranche Closed: Aggregate gross proceeds of $840,000, consisting of debentures and 16.8 million warrants.
  • Remaining Tranches: Intends to close one or two additional tranches for aggregate gross proceeds of up to $760,000.
  • Closing Schedule: Final tranche expected to close on or before March 6, 2026.
  • Use of Proceeds: Working capital and general corporate purposes.
  • Regulatory Status: Subject to receipt of necessary regulatory approvals, including TSX Venture Exchange approval.
  • Hold Period: All securities subject to a statutory hold period of four months and one day from issuance.
  • Fees: The company may pay finders' fees in connection with the upsized offering.
Read the original news release →

More from Telo Genomics Corp